Tracking Osteoarthritis Progress through Cationic Nanoprobe-Enhanced Photoacoustic Imaging of Cartilage.
Animals
Cartilage, Articular
/ diagnostic imaging
Contrast Media
/ chemistry
Disease Progression
Glycosaminoglycans
/ metabolism
Knee Joint
/ diagnostic imaging
Male
Melanins
/ chemistry
Mice
Nanoparticles
/ chemistry
Optical Imaging
/ methods
Osteoarthritis, Knee
/ diagnostic imaging
Photoacoustic Techniques
/ methods
Polylysine
/ chemistry
Rats, Sprague-Dawley
Cartilage
Cationic nanoprobes
Osteoarthritis
Photoacoustics imaging
Progression
Journal
Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
17
12
2019
revised:
21
03
2020
accepted:
02
04
2020
pubmed:
28
4
2020
medline:
16
4
2021
entrez:
28
4
2020
Statut:
ppublish
Résumé
A major obstacle in osteoarthritis (OA) theranostics is the lack of a timely and accurate monitoring method. It is hypothesized that the loss of anionic glycosaminoglycans (GAGs) in articular cartilage reflects the progression of OA. Thus, this study investigated the feasibility of photoacoustic imaging (PAI) applied for monitoring the in vivo course of OA progression via GAG-targeted cationic nanoprobes. The nanoprobes were synthesized through electrostatic attraction between poly-l-Lysine and melanin (PLL-MNPs). Cartilage explants with different concentrations of GAGs incubated with PLL-MNPs to test the relationship between GAGs content and PA signal intensity. GAG activity was then evaluated in vivo in destabilization of the medial meniscus (DMM) surgically-induced mouse model. To track OA progression over time, mice were imaged consistently for 10 weeks after OA-inducing surgery. X-ray was used to verify the superiority of PAI in detecting OA. The correlation between PAI data and histologic results was also analyzed. In vitro study demonstrated the ability of PLL-MNPs in sensitively detecting different GAGs concentrations. In vivo PAI exhibited significantly lower signal intensity from OA knees compared to normal knees. More importantly, PA signal intensity showed serial reduction over the course of OA, while X-ray showed visible joint destruction until 6 weeks. A decrease in GAGs content was confirmed by histologic examinations; moreover, histologic findings were well correlated with PAI results. Therefore, using cationic nanoprobe-enhanced PAI to detect the changes in GAG contents provides sensitive and consistent visualization of OA development. This approach will further facilitate OA theranostics and clinical translation. STATEMENT OF SIGNIFICANCE: The study of in vivo monitoring osteoarthritis (OA) is of high significance to tracking the trajectory of OA development and therapeutic monitoring. Here, we developed a cartilage-targeted cationic nanoprobe, poly-l-Lysine-melanin nanoparticles (PLL-MNPs), enhancing photoacoustic imaging (PAI) to monitor the progression of OA. The in vitro study demonstrated the ability of PLL-MNPs to detect different concentrations of GAGs with high sensitivity. We found that the contents of GAGs in vivo steadily decreased from the development of OA initial-stage to the end-point of our investigation via PAI; it reflected the course of OA in living subjects with high sensitivity. These results allow for further development in various aspects of OA research. It has potential for clinical translation and has a great impact on personalized medicine.
Identifiants
pubmed: 32339712
pii: S1742-7061(20)30198-7
doi: 10.1016/j.actbio.2020.04.001
pii:
doi:
Substances chimiques
Contrast Media
0
Glycosaminoglycans
0
Melanins
0
Polylysine
25104-18-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
153-162Informations de copyright
Copyright © 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest No conflict of interest exits in the submission of this manuscript, and manuscript is approved by authors for publication. I would like to declare on behalf of my co-authors that the manuscript has not been submitted or is not simultaneously being submitted elsewhere, is not at the time of submission under consideration by another journal or other publication, and that no portion of the data has been or will be published elsewhere while the manuscript is under review by the journal. We confirm that no portion of the data has been or will be published elsewhere while the manuscript is under review by Acta Biomaterialia. All the authors listed have approved the manuscript that is enclosed.